Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia
Status:
Terminated
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to test the safety of the combination of everolimus,
rituximab and bortezomib. Everolimus is a drug that works by preventing cells in your body
from growing and dividing. Information from basic and other clinical research suggests that
everolimus may also inhibit tumor growth in people with relapsed or refractory lymphoma. The
FDA has approved everolimus for the treatment of multiple myeloma, a cancer that is closely
related to Waldenstrom's Macroglobulinemia. Rituximab is approved by the FDA for the
treatment of non-Hodgkin's lymphoma, which included Waldenstrom's Macroglobulinemia.
Funding Source - FDA OOPD